<DOC>
	<DOCNO>NCT02542124</DOCNO>
	<brief_summary>In propose study , NM-IL-12 evaluate immunotherapy increase antitumor efficacy CTCL , reduce skin-related toxicity , combine low-dose TSEBT therapy . Determination maximum tolerate dose ( MTD ) NM-IL-12 plan study , rather , pre-defined start dose explore ; dose base two safety tolerability study NM-IL-12 healthy volunteer .</brief_summary>
	<brief_title>NM-IL-12 Cutaneous T-Cell Lymphoma ( CTCL ) Undergoing Total Skin Electron Beam Therapy ( TSEBT )</brief_title>
	<detailed_description>This single arm , open-label , non-randomized study NM-IL-12 dose combination low dose TSEBT CTCL patient . This study plan conduct 10 patient , 18 year old age , undergo low dose TSEBT 12 Gy 3-week period . The study initially enroll 4 patient expand enroll 6 additional patient ( total 10 patient ) depend presence absence Dose Modifying Criteria ( DMC ) . Decision whether de-escalate make first 4 patient follow 28 day first dose NM-IL-12 . Safety monitoring continue throughout whole period drug administration treatment discontinue intolerable toxicity disease progression occur period .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>1 . 18 year age old 2 . Biopsyconfirmed CD4+ mycosis fungoides Sézary syndrome , stage IB IIIB 3 . The patient eligible TSEBT 4 . Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 . 5 . Adequate bone marrow function : WBC &gt; 2000/μL ; platelet count &gt; 75,000/μL ; Neutrophil count &gt; 1000/μL , without use colony stimulate factor ( CSF ) . 6 . Required washout period prior therapy Topical therapy : 2 week Phototherapy ( PUVA ) : 4 week Local Skin Radiation Therapy ( &lt; 10 % skin surface ) : 4 week Retinoids : 4 week Interferons : 4 week Low dose methotrexate : 4 week HDAC inhibitor : 8 week 7 . Women childbearing potential must negative serum pregnancy test use accept highly effective method birth control throughout study 90 day dose must agree use effective contraception . 8 . Male patient must willing use appropriate method contraception ( e.g. , condom ) abstain sexual intercourse inform sexual partner must also use reliable method contraception study 90 day dose . 9 . Adequate hepatic function : bilirubin ≤1.5 x upper limit normal ( ULN ) , AST ≤2.5 x ULN , ALT ≤2.5 x ULN , alkaline phosphatase ( liver fraction ) ≤2.5 x ULN 10 . Adequate renal function : creatinine ≤1.5 x ULN 11 . Ability comply treatment schedule 1 . Biopsy confirm CD8+ CTCL histology 2 . Large cell transformation 3 . Prior systemic use immunosuppressive chemotherapy ( except low dose methotrexate ) and/or monoclonal antibody treatment CTCL 4 . Prior course TSEBT ( Note : localize skindirected radiotherapy allow administer least 4 week prior initiation study ) . 5 . Concomitant use anticancer therapy immune modifier . 6 . Prior allogeneic hematopoietic cell transplant . 7 . Any ongoing infection whether receive receive antibiotic receive intravenous antibiotic , antiviral , antifungal agent within 2 week prior start study drug . 8 . Known history human immunodeficiency virus ( HIV ) , hepatitis B C 9 . For woman estrogen base contraceptive , family history venous thromboembolism ( VTE ) and/or risk factor predispose VTE medical condition know associated VTE . 10 . History prior malignancy exception cervical intraepithelial neoplasia , nonmelanoma skin cancer , adequately treat localized prostate carcinoma ( PSA &lt; 1.0 ) . Patients history malignancy must undergo potentially curative therapy evidence disease five year 11 . Uncontrolled intercurrent illness , condition , circumstance could limit compliance study , include , limited following : acute chronic graft versus host disease , uncontrolled diabetes mellitus hypertension , psychiatric condition 12 . Any medical issue , include laboratory abnormality , deem Investigator likely interfere patient participation 13 . Unresolved toxicity previous anticancer therapy incomplete recovery surgery 14 . Major surgery within 12 week enrolment 15 . Medically significant cardiac event unstable cardiovascular function define : Symptomatic ischemia , unstable angina pectoris Uncontrolled clinically significant cardiac arrhythmia Symptomatic heart failure NYHA Class ≥ 3 Myocardial infarction cardiac surgery within 6 month prior enrollment 16 . Cerebrovascular event ( transient ischemic attack , stroke CNS bleed ) within last 12 month . 17 . Major bleed within last 6 month . 18 . Use investigational agent within 30 day prior enrollment duration study 19 . Pregnant lactate 20 . Unwilling unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CTCL</keyword>
	<keyword>Total Skin Electron Beam Therapy ( TSEBT )</keyword>
	<keyword>Mycosis fungoides</keyword>
	<keyword>Sézary syndrome</keyword>
	<keyword>recombinant human Interleukin-12 ( rHuIL-12 )</keyword>
	<keyword>T Cell</keyword>
</DOC>